Evotec SE

  • WKN: 566480
  • ISIN: DE0005664809
  • Land: Germany

IR-Ansprechpartner

Volker Braun
SVP, Head of Global Investor Relations & ESG

T: +49 40 560 81 775 
volker.braun@evotec.com

Gabriele Hansen
SVP, Head of Corporate Communications & Marketing

T: +49 40 560 81 255 
F: +49 40 560 81 333
investorrelations@evotec.com

Anja Ben Lekhal
Investor Relations Associate

Telefon: 49 40 56081 210
Email: anja.benlekhal@evotec.com

Anika Meier
Investor Relations Manager

T +49 40 560 839
anika.meier@evotec.com

Thore Schmidt
Investor Relations & ESG Coordinator

T +49 40 560 81 857
Email: thore.schmidt@evotec.com

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Neufassung der Dividendenpolitik der Allianz SE

02. Dezember 2021, 20:33

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021